Droperidol and diphenhydramine in the management of hyperemesis gravidarum

M. P. Nageotte, G. G. Briggs, Craig Towers, T. Asrat

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

OBJECTIVE: Hyperemesis gravidarum is a common pregnancy complication requiring hospitalization. Continuous droperidol infusion and bolus intravenous diphenhydramine were instituted as treatment. We compared the number and length of hospitalizations for hyperemesis gravidarum, readmissions for this diagnosis, and pregnancy outcome in patients receiving this treatment protocol with a historic group of patients receiving other forms of parenteral therapy for hyperemesis gravidarum. STUDY DESIGN: All patients hospitalized with a diagnosis of hyperemesis gravidarum between January 1992 and January 1994 were offered the droperidol-diphenhydramine protocol. These patients were compared with patients admitted between January 1990 and January 1992 with a diagnosis of hyperemesis gravidarum but who were not treated with droperidol at any time or with diphenhydramine as primary therapy for the control of severe nausea and vomiting. Data regarding the number and length of hospitalizations and readmissions for hyperemesis gravidarum were compared, as were maternal and perinatal outcomes. RESULTS: Patients treated with the droperidol-diphenhydramine protocol had significantly shorter hospitalizations (3.1 ± 1.9 vs 3.6 ± 2.4 days, p = 0.028), fewer days per pregnancy hospitalized for hyperemesis (3.5 ± 2.3 days vs 4.8 ± 4.3 days, p = 0.018), and fewer readmissions with this diagnosis (15.0% vs 31.5%, p = 0.015). There were no significant differences in maternal or perinatal outcomes. CONCLUSION: Droperidol and diphenhydramine infusion is a beneficial, cost-effective therapy for the treatment of hyperemesis gravidarum.

Original languageEnglish (US)
Pages (from-to)1801-1806
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume174
Issue number6
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Hyperemesis Gravidarum
Droperidol
Diphenhydramine
Hospitalization
Mothers
Therapeutics
Pregnancy Complications
Pregnancy Outcome
Clinical Protocols
Intravenous Infusions
Nausea
Vomiting
Costs and Cost Analysis
Pregnancy

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Droperidol and diphenhydramine in the management of hyperemesis gravidarum. / Nageotte, M. P.; Briggs, G. G.; Towers, Craig; Asrat, T.

In: American Journal of Obstetrics and Gynecology, Vol. 174, No. 6, 01.01.1996, p. 1801-1806.

Research output: Contribution to journalArticle

Nageotte, M. P. ; Briggs, G. G. ; Towers, Craig ; Asrat, T. / Droperidol and diphenhydramine in the management of hyperemesis gravidarum. In: American Journal of Obstetrics and Gynecology. 1996 ; Vol. 174, No. 6. pp. 1801-1806.
@article{bd8a82271d0a483c9c9495ce21f925f5,
title = "Droperidol and diphenhydramine in the management of hyperemesis gravidarum",
abstract = "OBJECTIVE: Hyperemesis gravidarum is a common pregnancy complication requiring hospitalization. Continuous droperidol infusion and bolus intravenous diphenhydramine were instituted as treatment. We compared the number and length of hospitalizations for hyperemesis gravidarum, readmissions for this diagnosis, and pregnancy outcome in patients receiving this treatment protocol with a historic group of patients receiving other forms of parenteral therapy for hyperemesis gravidarum. STUDY DESIGN: All patients hospitalized with a diagnosis of hyperemesis gravidarum between January 1992 and January 1994 were offered the droperidol-diphenhydramine protocol. These patients were compared with patients admitted between January 1990 and January 1992 with a diagnosis of hyperemesis gravidarum but who were not treated with droperidol at any time or with diphenhydramine as primary therapy for the control of severe nausea and vomiting. Data regarding the number and length of hospitalizations and readmissions for hyperemesis gravidarum were compared, as were maternal and perinatal outcomes. RESULTS: Patients treated with the droperidol-diphenhydramine protocol had significantly shorter hospitalizations (3.1 ± 1.9 vs 3.6 ± 2.4 days, p = 0.028), fewer days per pregnancy hospitalized for hyperemesis (3.5 ± 2.3 days vs 4.8 ± 4.3 days, p = 0.018), and fewer readmissions with this diagnosis (15.0{\%} vs 31.5{\%}, p = 0.015). There were no significant differences in maternal or perinatal outcomes. CONCLUSION: Droperidol and diphenhydramine infusion is a beneficial, cost-effective therapy for the treatment of hyperemesis gravidarum.",
author = "Nageotte, {M. P.} and Briggs, {G. G.} and Craig Towers and T. Asrat",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(96)70213-2",
language = "English (US)",
volume = "174",
pages = "1801--1806",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Droperidol and diphenhydramine in the management of hyperemesis gravidarum

AU - Nageotte, M. P.

AU - Briggs, G. G.

AU - Towers, Craig

AU - Asrat, T.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - OBJECTIVE: Hyperemesis gravidarum is a common pregnancy complication requiring hospitalization. Continuous droperidol infusion and bolus intravenous diphenhydramine were instituted as treatment. We compared the number and length of hospitalizations for hyperemesis gravidarum, readmissions for this diagnosis, and pregnancy outcome in patients receiving this treatment protocol with a historic group of patients receiving other forms of parenteral therapy for hyperemesis gravidarum. STUDY DESIGN: All patients hospitalized with a diagnosis of hyperemesis gravidarum between January 1992 and January 1994 were offered the droperidol-diphenhydramine protocol. These patients were compared with patients admitted between January 1990 and January 1992 with a diagnosis of hyperemesis gravidarum but who were not treated with droperidol at any time or with diphenhydramine as primary therapy for the control of severe nausea and vomiting. Data regarding the number and length of hospitalizations and readmissions for hyperemesis gravidarum were compared, as were maternal and perinatal outcomes. RESULTS: Patients treated with the droperidol-diphenhydramine protocol had significantly shorter hospitalizations (3.1 ± 1.9 vs 3.6 ± 2.4 days, p = 0.028), fewer days per pregnancy hospitalized for hyperemesis (3.5 ± 2.3 days vs 4.8 ± 4.3 days, p = 0.018), and fewer readmissions with this diagnosis (15.0% vs 31.5%, p = 0.015). There were no significant differences in maternal or perinatal outcomes. CONCLUSION: Droperidol and diphenhydramine infusion is a beneficial, cost-effective therapy for the treatment of hyperemesis gravidarum.

AB - OBJECTIVE: Hyperemesis gravidarum is a common pregnancy complication requiring hospitalization. Continuous droperidol infusion and bolus intravenous diphenhydramine were instituted as treatment. We compared the number and length of hospitalizations for hyperemesis gravidarum, readmissions for this diagnosis, and pregnancy outcome in patients receiving this treatment protocol with a historic group of patients receiving other forms of parenteral therapy for hyperemesis gravidarum. STUDY DESIGN: All patients hospitalized with a diagnosis of hyperemesis gravidarum between January 1992 and January 1994 were offered the droperidol-diphenhydramine protocol. These patients were compared with patients admitted between January 1990 and January 1992 with a diagnosis of hyperemesis gravidarum but who were not treated with droperidol at any time or with diphenhydramine as primary therapy for the control of severe nausea and vomiting. Data regarding the number and length of hospitalizations and readmissions for hyperemesis gravidarum were compared, as were maternal and perinatal outcomes. RESULTS: Patients treated with the droperidol-diphenhydramine protocol had significantly shorter hospitalizations (3.1 ± 1.9 vs 3.6 ± 2.4 days, p = 0.028), fewer days per pregnancy hospitalized for hyperemesis (3.5 ± 2.3 days vs 4.8 ± 4.3 days, p = 0.018), and fewer readmissions with this diagnosis (15.0% vs 31.5%, p = 0.015). There were no significant differences in maternal or perinatal outcomes. CONCLUSION: Droperidol and diphenhydramine infusion is a beneficial, cost-effective therapy for the treatment of hyperemesis gravidarum.

UR - http://www.scopus.com/inward/record.url?scp=0030009793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030009793&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(96)70213-2

DO - 10.1016/S0002-9378(96)70213-2

M3 - Article

VL - 174

SP - 1801

EP - 1806

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -